Alkermes (ALKS)
(Delayed Data from NSDQ)
$28.10 USD
-0.45 (-1.58%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $28.11 +0.01 (0.04%) 4:44 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Brokerage Reports
Alkermes plc [ALKS]
Reports for Purchase
Showing records 1 - 20 ( 297 total )
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Strong 2Q Driven By Its Proprietary Commercial Portfolio; Raise PT to $37
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Additional NT1 Data Further Demonstrates Efficacy And Safety of ALKS-2680; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
A Mixed Bag For 1Q as ALKS-2680 Moves Into Phase 2; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
2680 Again Shows Best-In-Class Potential, This Time in NT2
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Solid 4Q, Upbeat Outlook For the ''New'' Alkermes; PT up to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D